The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-02-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
As the article states, you don’t need marketing for cancer drugs, as the need is unfortunately already there, thus marketing for cancer drugs does not necessarily carry the same sales expense as do other drugs. We have all seen the “tiered plans” on what level drugs are listed with insurance coverage...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-13-2008
Filed under:
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, personalized medicine, Genomics, health insurance, Pharma, Prescriptions, Cancer, R and D, Science 2.0
In other words, this is called Business Intelligence. Lots of it out there to choose from and one from Microsoft specifically related to hospital management and budgets. Before the demise of Wall Street it wasn’t too long ago that I posted about the All Nighter they pulled to mine and try...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-26-2008
Filed under:
Filed under: Medically Related, Technology, Other Items of Interest, My Commentaries, Pharma, Biotech, Cancer, Business Intelligence, R and D, Wall Street, Pricing